<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:chebi fb="0" ids="31530">Edaravone</z:chebi> has potent free radical quenching and <z:chebi fb="11" ids="22586">antioxidant</z:chebi> actions </plain></SENT>
<SENT sid="1" pm="."><plain>The agent has been recently in commercial use for <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> patients </plain></SENT>
<SENT sid="2" pm="."><plain>In this study, we investigated the therapeutic effect of <z:chebi fb="0" ids="31530">edaravone</z:chebi> on severe carotid-territorial <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: <z:hpo ids='HP_0001297'>Stroke</z:hpo> patients with internal carotid <z:mp ids='MP_0006134'>artery occlusion</z:mp> and baseline NIH <z:hpo ids='HP_0001297'>Stroke</z:hpo> Scale Score &gt; or =15 were treated for 14 days with drip intravenous infusion of <z:chebi fb="0" ids="31530">edaravone</z:chebi> (n=30) and were compared with a historical control cohort of similar patients (n=31) </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="3" ids="17754">Glycerol</z:chebi> was also administered to <z:hpo ids='HP_0000001'>all</z:hpo> patients in both groups </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: <z:mpath ids='MPATH_124'>Infarct</z:mpath> volume (P&lt;0.02) and midline shift (P&lt;0.02) on CT performed on day 2 of the patients treated with <z:chebi fb="0" ids="31530">edaravone</z:chebi> were smaller than those without <z:chebi fb="0" ids="31530">edaravone</z:chebi> </plain></SENT>
<SENT sid="6" pm="."><plain>For patients with <z:chebi fb="0" ids="31530">edaravone</z:chebi>, <z:mpath ids='MPATH_124'>infarct</z:mpath> volume (P&lt;0.0001) and midline shift (P&lt;0.0001) on days 5-7 were greater than those on day 2 </plain></SENT>
<SENT sid="7" pm="."><plain>Hemorrhagic transformation of <z:mpath ids='MPATH_124'>infarcts</z:mpath> on day 2 was less severe in patients with than without <z:chebi fb="0" ids="31530">edaravone</z:chebi> (P&lt;0.03) </plain></SENT>
<SENT sid="8" pm="."><plain>Within 14 days after the <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:hpo ids='HP_0001297'>stroke</z:hpo>, 6 patients with <z:chebi fb="0" ids="31530">edaravone</z:chebi> (20%) and 14 without <z:chebi fb="0" ids="31530">edaravone</z:chebi> (45%) died directly of <z:hpo ids='HP_0001297'>stroke</z:hpo> (P&lt;0.03) </plain></SENT>
<SENT sid="9" pm="."><plain>Among <z:hpo ids='HP_0000001'>all</z:hpo> patients, only two treated with <z:chebi fb="0" ids="31530">edaravone</z:chebi> were independent without any assistance 8 weeks after the <z:hpo ids='HP_0003674'>onset</z:hpo> </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: <z:chebi fb="0" ids="31530">Edaravone</z:chebi> was associated with delayed evolution of <z:mpath ids='MPATH_124'>infarcts</z:mpath> and <z:hpo ids='HP_0000969'>edema</z:hpo> in patients with severe carotid-territorial <z:hpo ids='HP_0001297'>stroke</z:hpo> and decreased mortality during the <z:hpo ids='HP_0011009'>acute</z:hpo> stage </plain></SENT>
<SENT sid="11" pm="."><plain>The agent, however, failed to prevent evolution of <z:mpath ids='MPATH_124'>infarcts</z:mpath> and <z:hpo ids='HP_0000969'>edema</z:hpo> on later days, and did not significantly improve functional outcome among the surviving patients </plain></SENT>
</text></document>